ArticleCureus2025
Effects of Mild Therapeutic Hypothermia on Hemodynamic Support in Cardiogenic Shock After Acute Myocardial Infarction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myocardial infarction (AMI) is a prevalent etiology of cardiogenic shock (CS). Microcirculatory dysfunction may continue even when hemodynamic factors improve in CS because the condition is hemodynamically diverse. Patients with CS associated with AMI have been advised to utilize vasopressors and inotropic medications. The study aims to assess the effects of mild therapeutic hypothermia (MTH) on vasopressors and inotropes in patients with CS due to AMI.
methodsThe study was carried out on a cohort of 60 individuals who had CS after AMI. CS was operationally defined as the condition characterized by a systolic blood pressure below 90 mm Hg for a duration beyond 30 minutes or the presence of inotropes required to sustain a systolic blood pressure over 90 mm Hg without any indications of hypovolemia. Vasopressor and inotrope use were guided by cardiac specialists using a predefined hemodynamic protocol. Cardiogenic shock was defined by hypotension or inotrope dependence with evidence of hypoperfusion. Mean arterial blood pressure (MAP) and lactate levels were monitored every two hours for 30 hours to ensure treatment was based on objective criteria.
resultsNorepinephrine (NE) was significantly lower at four, six, eight, 10, 12, 14, 16, 18, and 20 hours in group I than in group II (p-value < 0.001) and was insignificantly different at 0, two, 22, 24, 26, 28, and 30 hours between both groups. The dobutamine dose was significantly higher at 10 hours in group I than in group II (p-value = 0.002) and was significantly lower at 14 hours in group I than in group II (p-value = 0.036) and was insignificantly different at 0, two, four, six, eight, 12, 16, 18, 20, 22, 24, 26, 28, and 30 hours between both groups.
conclusionsPatients treated with MTH to 33°C for 24 to 36 hours were associated with reduced NE requirements and higher MAP, along with increased dobutamine doses, compared to those without MTH. Arterial lactate rose initially with MTH but later declined. However, complications, clinical outcomes, and 30-day mortality were comparable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.